![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de Categorias
AlcoolismoAlzheimer E ParkinsonAnalgésicosAnti-InflamatóriosAnti-helmÃnticosAnti-viraisAntialérgicosAntibióticosAnticoncepcionaisAnticonvulsivantesAntidepressivosAntifúngicosArtriteAsmaCancroCirúrgiaColesterolCuidados Da PeleCuidados Para Los OjosDiabetesDisfunção EréctilDiuréticosDoenças CardiovascularesEnxaquecasH I VHipertensão ArterialObesidadeOsteoporosePerturbações MentaisPerturbações NeurológicasRelaxantes MuscularesSaúde FemininaSaúde MasculinaTrato GastrointestinalTrato RespiratórioTrato Urinário 19 Apr 2012 22:02:44
Forest 4Q profit falls 40 pct on generic Lexapro Proactive Investors USA & Canada Forest 4Q profit falls 40 pct on generic Lexapro CBS News Forest said sales of its blood pressure drug Bystolic rose 33 percent to $96.9 million. It also reported $24.9 million from its new depression treatment Viibryd. Its total drug revenue fell 9 percent to $996.9 million. The company reported greater ... Forest Laboratories Q1 profit drops, but results still top views Forest Laboratories outlines future growth strategy Forest Labs profit plunges as Lexapro loses patent19 Apr 2012 19:27:41
J&J 1Q profit jumps despite sales dip FederalNewsRadio.com J&J 1Q profit jumps despite sales dip FederalNewsRadio.com That was mainly from the sale of high blood pressure drug Bystolic to Forest Laboratories Inc. for $357 million during the quarter. Total US revenue fell 5 percent to $7.22 billion. That decline was offset by a 4 percent rise in international sales, ...19 Apr 2012 17:53:38
Johnson & Johnson Barters for EU Approval of Synthes DealJohnson & Johnson Barters for EU Approval of Synthes Deal Wall St. Cheat Sheet ... average estimate of 19 analysts, stemmed from a boost in sales of new drugs, including the prostate cancer medicine Zytiga. The healthcare giant also gained $357 million for selling its hypertension treatment Bystolic to Forest Laboratories (NYSE:FRX).
18 Apr 2012 20:16:07
Johnson & Johnson Raises Forecast; Will Other Drug Companies Follow Suit? Kapitall Blog Johnson & Johnson Raises Forecast; Will Other Drug Companies Follow Suit? DailyFinance The older drug sold was Bystolic , a hypertension treatment, to Forest Laboratories, and provided $357 million in cash, according to Bloomberg. "The medical device and pharmaceutical units look good and are improving, which are two legs of the stool," ... Johnson & Johnson Raises Forecast18 Apr 2012 12:40:08
Johnson & Johnson Reports 2012 First-Quarter ResultsJohnson & Johnson Reports 2012 First-Quarter Results The FINANCIAL During the quarter, Janssen Pharmaceutica NV completed the divestiture of its US patents and other US and Canadian intellectual property for Bystolic , which is currently approved in the US for the treatment of hypertension, to Forest Laboratories ...
18 Apr 2012 09:11:23
Johnson & Jonshon report spooks analystsJohnson & Jonshon report spooks analysts Cherry Hill Courier Post That was mainly from the sale of high blood pressure drug Bystolic to Forest Laboratories Inc. for $357 million during the quarter. Total US revenue fell 5 percent to $7.22 billion. That decline was offset by a 4 percent rise in international sales, ...
17 Apr 2012 21:24:01
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per ...Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per ... EON: Enhanced Online News (press release) Sales of Bystolic  (nebivolol), a beta-blocker for the treatment of hypertension, were $96.9 million, an increase of 32.6% over the year-ago period. Sales of Savella (milnacipran HCl), a selective serotonin norepinephrine dual reuptake inhibitor ... Forest Labs Earnings Call Nuggets: Guidance and New Product Catalysts
17 Apr 2012 21:20:56
Johnson & Johnson Management Discusses Q1 2012 Results - Earnings Call TranscriptJohnson & Johnson Management Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha 2012 results include the gain related to the divestiture of Bystolic while 2011 results included the gain related to the equity investment in Crucell. Excluding special items, the effective tax rate was 22.8% in the first quarter of 2012, ...
|
|
Choose Your language:
Pesquisa no site:
Testemunhos
Olá.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mais vendidos|Política|Questões Mais Frequentes|Testemunhos|Contacte-nos|Sitemap |
|
|
|
|
| |